Cariprazine
- Generic Name
- Cariprazine
- Brand Names
- Vraylar, Reagila
- Drug Type
- Small Molecule
- Chemical Formula
- C21H32Cl2N4O
- CAS Number
- 839712-12-8
- Unique Ingredient Identifier
- F6RJL8B278
- Background
Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary. It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT receptors and as an antagonist at serotonin 5-HT receptors. Cariprazine has been investigated in a variety of psychiatric disorders, including schizophrenia, bipo...
- Indication
Cariprazine is indicated for the treatment of schizophrenia in adults to manage both positive and negative symptoms. It is also indicated to monotherapy for acute management of manic or mixed episodes associated with bipolar I disorder (bipolar mania) in adults, and acute management of depressive episodes associated with bipolar I disorder (bipolar depressio...
- Associated Conditions
- Bipolar Disorder With Manic or Mixed Episodes, Depressive Episodes, Schizophrenia
- Associated Therapies
- -
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
- First Posted Date
- 2011-11-10
- Last Posted Date
- 2018-05-01
- Lead Sponsor
- Forest Laboratories
- Target Recruit Count
- 819
- Registration Number
- NCT01469377
- Locations
- ๐บ๐ธ
Forest Investigative Site 070, Houston, Texas, United States
๐ช๐ชForest Investigative Site 202, Vรตru, Estonia
๐ช๐ชForest Investigative Site 208, Tartu, Estonia
A Study of Cariprazine in the Prevention of Relapse of Symptoms in Participants With Schizophrenia
- First Posted Date
- 2011-08-08
- Last Posted Date
- 2018-07-06
- Lead Sponsor
- Forest Laboratories
- Target Recruit Count
- 765
- Registration Number
- NCT01412060
- Locations
- ๐บ๐ธ
Forest Investigative Site 002, Oceanside, California, United States
๐บ๐ธForest Investigative Site 008, Long Beach, California, United States
๐บ๐ธForest Investigative Site 011, Little Rock, Arkansas, United States
Safety, Tolerability, and Efficacy of Cariprazine in Participants With Bipolar Depression
- First Posted Date
- 2011-07-18
- Last Posted Date
- 2018-05-01
- Lead Sponsor
- Forest Laboratories
- Target Recruit Count
- 584
- Registration Number
- NCT01396447
- Locations
- ๐บ๐ธ
Forest Investigative Site 007, Dallas, Texas, United States
๐บ๐ธForest Investigative Site 038, Atlanta, Georgia, United States
๐บ๐ธForest Investigative Site 005, Atlanta, Georgia, United States
Effects of Cariprazine on Cardiac Repolarization in Patients With Schizophrenia
- First Posted Date
- 2011-06-20
- Last Posted Date
- 2012-02-08
- Lead Sponsor
- Forest Laboratories
- Target Recruit Count
- 129
- Registration Number
- NCT01376076
- Locations
- ๐บ๐ธ
Forest Investigative Site 003, Houston, Texas, United States
๐บ๐ธForest Investigative Site 002, Willingboro, New Jersey, United States
๐บ๐ธForest Investigative Site 004, Long Beach, California, United States
Safety and Efficacy of Cariprazine in Schizophrenia
- First Posted Date
- 2010-04-15
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- Forest Laboratories
- Target Recruit Count
- 446
- Registration Number
- NCT01104779
- Locations
- ๐ฎ๐ณ
Forest Investigative Site 503, Ahmedabad, Gujarat, India
๐จ๐ดForest Investigative Site 604, Pereira, Risaralda, Colombia
๐ฎ๐ณForest Investigative Site 505, Vijayawada, Andhra Pradesh, India
Safety and Efficacy of Cariprazine in Patients With Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2010-04-15
- Last Posted Date
- 2018-10-29
- Lead Sponsor
- Forest Laboratories
- Target Recruit Count
- 617
- Registration Number
- NCT01104766
- Locations
- ๐บ๐ธ
Synergy Clinical Research of Escondido, Escondido, California, United States
๐บ๐ธExcell Research, Inc, Oceanside, California, United States
๐บ๐ธColorado Clinical Trials, Inc., Littleton, Colorado, United States
Long-term Study of Cariprazine in Patients With Schizophrenia
- First Posted Date
- 2010-04-15
- Last Posted Date
- 2019-07-26
- Lead Sponsor
- Forest Laboratories
- Target Recruit Count
- 752
- Registration Number
- NCT01104792
- Locations
- ๐บ๐ธ
Forest Investigative Site 044, Rockville, Maryland, United States
๐บ๐ธForest Investigative Site 007, Flowood, Mississippi, United States
๐บ๐ธForest Investigative Site 082, North Miami, Florida, United States
Long-term Safety and Tolerability of Cariprazine for Bipolar I Disorder
- First Posted Date
- 2010-02-01
- Last Posted Date
- 2019-06-13
- Lead Sponsor
- Forest Laboratories
- Target Recruit Count
- 403
- Registration Number
- NCT01059539
- Locations
- ๐บ๐ธ
Forest Investigative Site 015, Springdale, Arkansas, United States
๐บ๐ธForest Investigative Site 004, Garden Grove, California, United States
๐บ๐ธForest Investigative Site 010, Carson, California, United States
Safety and Efficacy of Cariprazine for Bipolar I Disorder
- First Posted Date
- 2010-01-29
- Last Posted Date
- 2017-04-12
- Lead Sponsor
- Forest Laboratories
- Target Recruit Count
- 497
- Registration Number
- NCT01058668
- Locations
- ๐บ๐ธ
Forest Investigative Site 025, St. Louis, Missouri, United States
๐ท๐ดForest Investigative Site 206, Bucuresti, Romania
๐บ๐ฆForest Investigative Site 307, Kharkiv, Ukraine
Safety and Efficacy of Cariprazine for Mania
- First Posted Date
- 2010-01-28
- Last Posted Date
- 2017-04-17
- Lead Sponsor
- Forest Laboratories
- Target Recruit Count
- 323
- Registration Number
- NCT01058096
- Locations
- ๐ฎ๐ณ
Forest Investigative Site 112, Vizag, Andhra Pradesh, India
๐ฎ๐ณForest Investigator Site 108, Varanasi, Durgakund, India
๐ฎ๐ณForest Investigative Site 106, Vijayawada, Andhra Pradesh, India
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.